Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP911083.RASLkXpW3GjLGnvdsGUQv1Z4FSIbY5XXN7_2uP2ykr5yc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP911083.RASLkXpW3GjLGnvdsGUQv1Z4FSIbY5XXN7_2uP2ykr5yc130_assertion type Assertion NP911083.RASLkXpW3GjLGnvdsGUQv1Z4FSIbY5XXN7_2uP2ykr5yc130_head.
- NP911083.RASLkXpW3GjLGnvdsGUQv1Z4FSIbY5XXN7_2uP2ykr5yc130_assertion description "[We retrospectively studied four cases of t-MDS/AML among 210 (1.9%) consecutive patients with CLL treated at a single center with fludarabine and cyclophosphamide (FC) either as the first- or second-line therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP911083.RASLkXpW3GjLGnvdsGUQv1Z4FSIbY5XXN7_2uP2ykr5yc130_provenance.
- NP911083.RASLkXpW3GjLGnvdsGUQv1Z4FSIbY5XXN7_2uP2ykr5yc130_assertion evidence source_evidence_literature NP911083.RASLkXpW3GjLGnvdsGUQv1Z4FSIbY5XXN7_2uP2ykr5yc130_provenance.
- NP911083.RASLkXpW3GjLGnvdsGUQv1Z4FSIbY5XXN7_2uP2ykr5yc130_assertion SIO_000772 21775097 NP911083.RASLkXpW3GjLGnvdsGUQv1Z4FSIbY5XXN7_2uP2ykr5yc130_provenance.
- NP911083.RASLkXpW3GjLGnvdsGUQv1Z4FSIbY5XXN7_2uP2ykr5yc130_assertion wasDerivedFrom befree-2016 NP911083.RASLkXpW3GjLGnvdsGUQv1Z4FSIbY5XXN7_2uP2ykr5yc130_provenance.
- NP911083.RASLkXpW3GjLGnvdsGUQv1Z4FSIbY5XXN7_2uP2ykr5yc130_assertion wasGeneratedBy ECO_0000203 NP911083.RASLkXpW3GjLGnvdsGUQv1Z4FSIbY5XXN7_2uP2ykr5yc130_provenance.